ArticleOncology and therapy2026
Time and Resource Implications of Subcutaneous Daratumumab-Based versus Intravenous Isatuximab-Based Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible.
Article in Oncology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Time toxicity in cancer care: a systematic review of definitions and measurement methods.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMultiple myeloma (MM) treatment is associated with significant healthcare provider (HCP) and patient time burden due to the frequency and duration of hospital visits for treatment. This study evaluated impacts on HCP and patient time burden of daratumumab subcutaneous (SC)-based versus isatuximab intravenous (IV)-based regimens in patients with newly diagnosed MM who are transplant ineligible.
methodsAn online survey of HCPs (hemato-oncology specialists, nurse practitioners, and hospital pharmacists) was conducted in nine European countries and Egypt. Respondents provided estimates of HCP and patient time associated with individual SC and IV treatment steps. These survey data and published dosing schedules informed development of a resource utilization model to compare overall time burden for SC and IV regimens over a 2-year cumulative period.
resultsHCPs reported savings in median active working time per treatment visit for steps before, during and after administration of daratumumab SC versus isatuximab IV treatments, with a total median saving of up to 135 min (39.1% reduction). HCPs also reported less median patient time per visit with daratumumab SC versus isatuximab IV treatments, with a total median saving of up to 115 min (27.1% reduction). Over 2 years, reduced time for SC versus IV administration, coupled with the less frequent dosing schedule for daratumumab versus isatuximab, resulted in marked time savings for HCPs and patients with D-Rd SC (HCPs: 221 h saved [64.2% reduction]; patients: 224 h [61.2% reduction]), D-VRd SC (HCPs: 157 h [45.6% reduction]; patients: 149 h [40.7% reduction]), and D-VMP SC (HCPs: 147 h [42.7% reduction]; patients: 140 h [38.3% reduction]) versus Isa-VRd IV.
conclusionsThis study demonstrated notable time savings with daratumumab SC-based versus isatuximab IV-based regimens in patients with newly diagnosed MM who are transplant ineligible based on SC versus IV administration and less frequent daratumumab dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.